Literature DB >> 10848215

Neuroprotection: a new treatment modality for glaucoma?

M Schwartz1, E Yoles.   

Abstract

It is now commonly accepted that glaucoma is a neurodegenerative disease of the optic nerve. Thus, at any given time, there are neurons that, though still viable, are vulnerable to the hostile extracellular milieu and are therefore amenable to neuroprotective therapy. Neuroprotection refers to any intervention, either external to the optic nerve or internally, that will lead to an intracellular change in the balance between survival and death signals in favor of survival. Several potential sites and modalities for such intervention may exist. When designing neuroprotective therapy, ways must be sought to recruit the physiologic self-repair mechanisms awakened by the primary or secondary risk factors. These mechanisms appear to be insufficiently effective when in their natural state, but they may be simulated or boosted by appropriate therapeutic compounds or cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10848215     DOI: 10.1097/00055735-200004000-00007

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  11 in total

1.  Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma.

Authors:  H Schori; J Kipnis; E Yoles; E WoldeMussie; G Ruiz; L A Wheeler; M Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

2.  T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure.

Authors:  Sharon Bakalash; Gil Ben-Shlomo; Gil Ben Shlomo; Eyal Aloni; Iftach Shaked; Larry Wheeler; Ron Ofri; Michal Schwartz
Journal:  J Mol Med (Berl)       Date:  2005-08-12       Impact factor: 4.599

Review 3.  Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders.

Authors:  M Schwartz
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

Review 4.  Neuroprotection for treatment of glaucoma in adults.

Authors:  Dayse F Sena; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2017-01-25

5.  T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies.

Authors:  J Kipnis; E Yoles; Z Porat; A Cohen; F Mor; M Sela; I R Cohen; M Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 6.  Neuroprotection for treatment of glaucoma in adults.

Authors:  Dayse F Sena; Kanchan Ramchand; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2010-02-17

Review 7.  Neuroprotection for treatment of glaucoma in adults.

Authors:  Dayse F Sena; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

8.  Association of known common genetic variants with primary open angle, primary angle closure, and pseudoexfoliation glaucoma in Pakistani cohorts.

Authors:  Shazia Micheal; Humaira Ayub; Muhammad Imran Khan; Bjorn Bakker; Frederieke E Schoenmaker-Koller; Mahmood Ali; Farah Akhtar; Wajid Ali Khan; Raheel Qamar; Anneke I den Hollander
Journal:  Mol Vis       Date:  2014-11-04       Impact factor: 2.367

Review 9.  Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.

Authors:  Despina Kokona; Panagiota-Christina Georgiou; Mihalis Kounenidakis; Foteini Kiagiadaki; Kyriaki Thermos
Journal:  Neural Plast       Date:  2016-01-06       Impact factor: 3.599

Review 10.  Current perspective of neuroprotection and glaucoma.

Authors:  Kailin Tian; Shannon Shibata-Germanos; Milena Pahlitzsch; M Francesca Cordeiro
Journal:  Clin Ophthalmol       Date:  2015-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.